PHARMACEUTICAL INDUSTRY

Pharmaceutical Industry



Table of Contents

Introduction3

Industry Environment Analysis3

Rivalry4

Barriers to Entry4

Substitutes4

Suppliers4

Buyers4

BCG Matrix4

PEST Analysis4

Political4

Economic4

Social4

Technological4

Opportunities4

Threats4

Emerging Trends4

The communication4

Conclusion4

References4

Pharmaceutical Industry

Introduction

In 1897, Felix Hoffmann created a new industry. He found a way of adding a cluster of two extra carbon and five extra hydrogen atoms to a substance extracted from willow bark. The result is known to chemists as acetylsalicylic acid. To everyone else it is known as aspirin. It turned Bayer, the dye-maker Hoffmann worked for, into the world's first modern drug company." Geoffrey Carr, The Alchemists, The Economist - Feb 19th 1998. Today's Pharmaceutical Industry is characterized by several important factors that influence the business environment in which each company operates (Porter, 1980, 36-39):

Severe competition from capitally strong competitors

Strict government regulations

Long approval wait time

Technology as an important factor

Lower levels of marketing and customer relations in comparison to other markets

Sales share of the world's top 75 prescription medicines 2002

Industry Environment Analysis

In 1997, the $65 billion industry was composed of three strategic groups: patented prescription drugs, generic prescription drugs and over-the-counter drugs. Firms such as Merck, SmithKline, Eli Lilly and others produced various types of brand name drugs. Pharmaceutical companies spent huge amounts of money on development.

The products produced by companies are very innovative. Many companies market up to ten (10) "blockbuster" drugs each year. These drugs have a patent life of seventeen (17) years. However, since it takes on average twelve (12) years to get the drug to market, manufactures have only five (5) years in the market to recoup their heavy research and development costs. After the patent expires we move to our next strategic group; the generic prescription drug makers (Ranchhod, 2004, 23-25).

Annual Census of Production (ONS)

Generic drug manufactures are usually first developed by the patented prescription drug makers (or they can even be developed by the over-the-counter manufactures). They have little to no research and development costs. They have little to no marketing budgets and much lower overall costs. As a result, generic drug manufacturers can sell their products at lower prices (Coyne, 2005, 3-14).

The third strategic group within the pharmaceutical industry is the over-the-counter drug manufacturer. These products have a very broad range. They include items such as cold medicine for a common cold, aspirin for a headache, and antacid relief for the stomach.

The three above-mentioned groups pursue different strategies and operate in different environments. Porter's five-force model can be applied to illustrate the differences between the groups. Below is a summary of each force and the corresponding strategic group Marcia, 2004, 305):

Rivalry

Prescription: High, patents protect each company when a drug is first developed. However, production costs are high (over $6 million) and only 20% recoup their costs.

Generic: High, there is the generic brand versus the name brand. Why should we pay more for the same exact product? Many prescription drug plans have a higher deductible for name brand drugs than generic drugs. Keeping costs lower than your competition is key.

Over-the-counter: High, there is the store brand versus the name brand. Why should we pay more for the same exact product? ...